PFD is a small‐molecule inhibitor that is FDA‐approved for the treatment of idiopathic pulmonary fibrosis, and its mechanism of action is thought to include inhibition of TGF‐β1 activity.43 This evidence concerns the gene TGFB1 and pulmonary fibrosis.